gochugaru korean chile
Selected indexed studies
- Stroke genetics informs drug discovery and risk prediction across ancestries. (Nature, 2022) [PMID:36180795]
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. (J Clin Oncol, 2023) [PMID:36306479]
- Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. (JAMA, 2024) [PMID:38762797]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. (2024) pubmed
- Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021. (2024) pubmed
- Stroke genetics informs drug discovery and risk prediction across ancestries. (2022) pubmed
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. (2023) pubmed
- Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. (2024) pubmed
- Global, regional, and national cascades of diabetes care, 2000-23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study. (2025) pubmed
- The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact. (2024) pubmed
- Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. (2025) pubmed
- Global cost of silencing science. (2025) pubmed
- Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. (2025) pubmed